Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Unexpected Worsening of Pemphigus Vulgaris After Rituximab: A Report of Three Cases Publisher Pubmed



Mahmoudi H1 ; Balighi K1 ; Tavakolpour S1 ; Daneshpazhooh M1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran

Source: International Immunopharmacology Published:2019


Abstract

During the recent decade, several studies have confirmed the high efficacy of targeting the CD20 molecules using rituximab (RTX). Recently, RTX has been suggested as the first-line treatment of pemphigus vulgaris (PV). In this study, the records of all the PV patients, who had received RTX in Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences between the 2009 and 2017, have been reviewed for any sign of disease worsening within three months after treatment. We have observed three PV patients from 612 RTX-exposed patients, who had experienced worsening of disease more than one time after discrete RTX cycles after the first infusion of RTX. All patients were successfully managed with different strategies (e.g., increase in steroid dosag intravenous immunoglobulin [IVIg], and plasmapheresis). In conclusion, despite the high efficacy of RTX therapy in PV patients, the exceptional risk of post-RTX disease worsening exists. Further studies are encouraged to develop (bio)markers to predict possible unexpected worsening of PV patients exposed to RTX. © 2019 Elsevier B.V.
Related Docs
View other Related Docs
1. Sixteen-Year History of Rituximab Therapy for 1085 Pemphigus Vulgaris Patients: A Systematic Review, International Immunopharmacology (2018)
2. Efficacy and Safety of Biosimilar Rituximab in Patients With Pemphigus Vulgaris: A Prospective Observational Study, Journal of Dermatological Treatment (2021)
3. Rituximab in Practice: Clinical Evaluation of Patients With Pemphigus After Rituximab Administration, Dermatologic Therapy (2021)
4. Intralesional Injection of Biosimilar Rituximab in Recalcitrant Mucocutaneous Lesions of Patients With Pemphigus Vulgaris: A Pilot Study, Dermatologic Therapy (2020)
5. Comparing Early and Late Treatments With Rituximab in Pemphigus Vulgaris: Which One Is Better?, Archives of Dermatological Research (2019)
6. Single-Nucleotide Polymorphisms Associated With Pemphigus Vulgaris: Potent Markers for Better Treatment and Personalized Medicine, International Journal of Immunogenetics (2020)
7. Updated S2k Guidelines on the Management of Pemphigus Vulgaris and Foliaceus Initiated by the European Academy of Dermatology and Venereology (Eadv), Journal of the European Academy of Dermatology and Venereology (2020)
8. Drug-Induced Pemphigus: A Systematic Review of 170 Patients, International Immunopharmacology (2021)
Experts (# of related papers)
View all Related Experts
Maryam Daneshpajooh (26)
Kamran Balighi (21)
Other Related Docs
9. Investigating Expression Pattern of Eight Immune-Related Genes in Pemphigus Patients Compared With the Healthy Controls and After Rituximab Therapy: Potential Roles of Ctla4 and Fcgr3a Genes Expression in Outcomes of Rituximab Therapy, Dermatologic Therapy (2020)
10. A Systematic Review on Efficacy, Safety, and Treatment-Durability of Low-Dose Rituximab for the Treatment of Pemphigus: Special Focus on Covid-19 Pandemic Concerns, Immunopharmacology and Immunotoxicology (2021)
11. Short-Term Clinical and Serological Follow-Up With Conventional and Conformational Anti-Desmoglein Antibodies in Treatment-Naive and Previously Treated Patients With Pemphigus Vulgaris After Receiving Rituximab, International Journal of Women's Dermatology (2019)
12. Comparing the Short-Term Therapeutic Effects and Safety Profiles of Rituximab Therapy in Pemphigus Vulgaris Patients Either Early Treated or Later Than Six Months, Journal of Dermatological Treatment (2019)
13. Paradoxical Reaction to Rituximab in Patients With Pemphigus: A Report of 10 Cases, Immunopharmacology and Immunotoxicology (2020)
14. Prevalence of Fungal Infections in Pemphigus Patients: A Systematic Review and Meta-Analysis, Mycoses (2024)
15. Iranian Guideline for Rituximab Therapy in Pemphigus Patients, Dermatologic Therapy (2019)
16. Tofacitinib As the Potent Treatment for Refractory Pemphigus: A Possible Alternative Treatment for Pemphigus, Dermatologic Therapy (2018)
17. Pathogenic and Protective Roles of Cytokines in Pemphigus: A Systematic Review, Cytokine (2020)
18. Towards Personalized Medicine for Patients With Autoimmune Diseases: Opportunities and Challenges, Immunology Letters (2017)
19. “Change Over Time in the Treatment of Pemphigus Vulgaris Between 2004 and 2016 in Iran”: A Multiple Cross-Sectional Study, Dermatologic Therapy (2019)
20. Pemphigus Trigger Factors: Special Focus on Pemphigus Vulgaris and Pemphigus Foliaceus, Archives of Dermatological Research (2018)
21. Applicability of Glucocorticoid Toxicity Index in Pemphigus: Comparison Between Two Groups of Rituximab-Treated and Rituximab-Naive Patients, Dermatologic Therapy (2022)
22. Anti-Desmoglein-1 Levels As Predictor of Prednisolone Tapering in Pemphigus Vulgaris Patients Treated With Rituximab, Dermatologic Therapy (2018)
23. Rituximab in Childhood and Juvenile Autoimmune Bullous Diseases As First-Line and Second-Line Treatment: A Case Series of 13 Patients, Journal of Dermatological Treatment (2020)
24. A Systematic Review on Efficacy, Safety and Treatment Durability of Intravenous Immunoglobulin in Autoimmune Bullous Dermatoses: Special Focus on Indication and Combination Therapy, Experimental Dermatology (2023)
25. Rituximab Therapy Improves Recalcitrant Pemphigus Vulgaris, EXCLI Journal (2015)
26. The Efficacy of Rituximab in Patients With Mucous Membrane Pemphigoid, Journal of Dermatological Treatment (2022)
27. Burden of Pemphigus Vulgaris With a Particular Focus on Women: A Review, International Journal of Women's Dermatology (2022)
28. Rituximab Exhibits a Better Safety Profile When Used As a First Line of Treatment for Pemphigus Vulgaris: A Retrospective Study, International Immunopharmacology (2021)
29. Pharmacogenetics: A Strategy for Personalized Medicine for Autoimmune Diseases, Clinical Genetics (2018)
30. Elevated Serum Level of B-Cell Activating Factor (Baff) After Rituximab Therapy in Pemphigus Vulgaris Patients Suggests a Possible Therapeutic Efficacy of B-Cell Depletion Therapies Combined With Anti-Baff Agents, International Journal of Dermatology (2023)